Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally.
High growth potential with adequate balance sheet.
Share Price & News
How has Misonix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MSON's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: MSON underperformed the US Medical Equipment industry which returned 6.3% over the past year.
Return vs Market: MSON underperformed the US Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is Misonix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWould Misonix (NASDAQ:MSON) Be Better Off With Less Debt?
3 months ago | Simply Wall StThings Look Grim For Misonix, Inc. (NASDAQ:MSON) After Today's Downgrade
4 months ago | Simply Wall StWhen Can We Expect A Profit From Misonix, Inc. (NASDAQ:MSON)?
Is Misonix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MSON is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: MSON is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MSON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MSON is good value based on its PB Ratio (1.2x) compared to the US Medical Equipment industry average (3.7x).
How is Misonix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSON is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: MSON is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MSON's is expected to become profitable in the next 3 years.
Revenue vs Market: MSON's revenue (25.6% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: MSON's revenue (25.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MSON's Return on Equity is forecast to be high in 3 years time
How has Misonix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MSON is currently unprofitable.
Growing Profit Margin: MSON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MSON is unprofitable, and losses have increased over the past 5 years at a rate of -56% per year.
Accelerating Growth: Unable to compare MSON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSON is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).
Return on Equity
High ROE: MSON has a negative Return on Equity (-7.26%), as it is currently unprofitable.
How is Misonix's financial position?
Financial Position Analysis
Short Term Liabilities: MSON's short term assets ($69.4M) exceed its short term liabilities ($14.1M).
Long Term Liabilities: MSON's short term assets ($69.4M) exceed its long term liabilities ($40.1M).
Debt to Equity History and Analysis
Debt Level: MSON's debt to equity ratio (25.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MSON's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MSON has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MSON has less than a year of cash runway if free cash flow continues to reduce at historical rates of 64.8% each year
What is Misonix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MSON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MSON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MSON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MSON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MSON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stavros Vizirgianakis (50yo)
Mr. Stavros George Vizirgianakis, B.Com., has been the Chief Executive Officer of Misonix, Inc. since December 19, 2016 and served as it's President until September 2019. Mr. Vizirgianakis served as an Int ...
CEO Compensation Analysis
Compensation vs Market: Stavros's total compensation ($USD554.15K) is below average for companies of similar size in the US market ($USD1.34M).
Compensation vs Earnings: Stavros's compensation has increased whilst the company is unprofitable.
|CEO & Director||3.58yrs||US$554.15k||9.5% $18.1m|
|CFO, Treasurer & Secretary||3.83yrs||US$602.94k||0.027% $51.5k|
|Chief Operating Officer||1.33yrs||US$538.71k||0.0081% $15.5k|
|Senior Vice President of Global Sales & Marketing||5.17yrs||US$538.19k||0.066% $125.9k|
|President||0.83yr||no data||1.41% $2.7m|
|Senior Vice President of Sales||0.83yr||no data||no data|
|Chief Medical Officer||no data||no data||no data|
Experienced Management: MSON's management team is considered experienced (2.5 years average tenure).
|CEO & Director||3.58yrs||US$554.15k||9.5% $18.1m|
|Independent Director||0.83yr||no data||no data|
|Independent Director||5.5yrs||US$167.72k||0.040% $76.7k|
|Independent Chairman of the Board||0.75yr||no data||no data|
|Independent Director||2yrs||US$191.01k||no data|
Experienced Board: MSON's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MSON insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.2%.
Misonix, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Misonix, Inc.
- Ticker: MSON
- Exchange: NasdaqGM
- Founded: 1959
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$190.110m
- Shares outstanding: 17.36m
- Website: https://www.misonix.com
Number of Employees
- Misonix, Inc.
- 1938 New Highway
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MSON||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jan 1992|
|MX9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1992|
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally. The company’s products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/10 00:05|
|End of Day Share Price||2020/07/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.